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With the exclusive presence of the pancreatic CCK-2 receptors on the pancreatic delta cells of six diﬀerent species, this study was
undertaken to determine the role of cholecystokinin and gastrin on growth of these somatostatin (SS) cells. For this study, the
SS-RIN-14B cells were used in culture and their growth was evaluated by cell counting. Results. To our surprise, we established by
Western blot that these RIN cells possess the two CCK receptor subtypes, CCK-1 and CCK-2. Occupation of the CCK-1 receptors
by caerulein, a CCK analog, led to inhibition of cell proliferation, an eﬀect prevented by a speciﬁc CCK-1 receptor antagonist.
Occupation of the CCK-2 receptors by the gastrin agonist pentagastrin had no eﬀect on cell growth. Proliferation was not aﬀected
by SS released from these cells but was inhibited by exogenous SS. Conclusions. Growth of the SS-RIN-14B cells can be negatively
aﬀected by occupation of their CCK-1 receptors and by exogenous somatostatin.
Copyright © 2009 K. El-Kouhen and J. Morisset. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
In the pancreas, the cholecystokonin-2 receptor (CCK-2R),
formerlytheCCK-Breceptor,hasbeenlocatedexclusivelyon
the somatostatin-delta cells of six diﬀerent species, including
man [1]. To date, nothing is known about the role of this
CCK receptor subtype on the physiology of these delta
cells. It has been reported however that chronic injections
of caerulein, a CCK analog, and secretin caused signiﬁcant
increases in rat pancreatic somatostatin (SS) content without
any eﬀect on total delta cell numbers [2]. Similar changes
in SS contents were also observed with the same hormones
combination in islets cultured for 10 days with no diﬀerence
in islets’ total DNA contents [3].
It was initially demonstrated that gastrin and CCK-
8, at relatively high doses, caused a quick and transient
twofoldincreaseinSSreleasebytheperfusedcaninepancreas
[4]. When CCK-8 was infused at a dose that stimulates
the secretion of protein in the pancreatic juice of dogs to
the levels normally observed with a meal [5], SS in the
pancreatic vein rose immediately about 2-fold above basal
and remained elevated for the 15 minutes of the hormone
infusion [6]. These data indicate that gastrin and CCK
can induce SS secretion from the pancreatic gland which
was later directly conﬁrmed from rat islet cell in culture
[7].
In order to have an exclusive and direct access to the pan-
creatic somatostatin cells and to avoid mixtures of cell types
from islet cell cultures, investigators established and cloned
a transplantable rat islet cell tumor which secretes insulin
and somatostatin [8]. Clones of the original somatostatin
cell line were used to study somatostatin secretion (RINT3),
intracellular signalling pathways activated in response to
CCK receptor subtypes occupation (RIN1027-B2) and CCK
receptor subtypes characterization and SS release (RIN-14B)
[9–11].
This study was undertaken to establish the presence
of the two CCK receptor subtypes on the RIN-14B cells
and to determine if one or both of these types can aﬀect
growth of these cells. To our knowledge, no study has yet
been performed to explore if the gastrointestinal hormones
CCK and gastrin, two speciﬁc CCK-1 and CCK-2 receptors
agonists, respectively, have any eﬀects on growth of the
pancreatic somatostatin cells.2 International Journal of Endocrinology
2.MaterialsandMethods
Products. Somatostatin-14 (SS-14) was purchased from
Bachem Bioscience (King of Prussia, Pa, USA). Pentagastrin
(PG) was purchased from Sigma-Aldrich (Oakville, ON,
Canada). Caerulein (Cae) was generously given by Dr. R.
de Castiglione, Farmitalia (Milan, Italy). L-364,718 and L-
365,260 were gifts from Dr. V. J. Lotti, Merck Sharp and
Dohme Research Laboratories (West Point, Pa). The RIN-
14B cells were obtained from ATCC (Manassas, Va, USA).
The COS cells were gifts from Dr. M. Tremblay (McGill
Cancer Centre, Montreal, Canada). Cell culture media
reagents were obtained from Life Technologies (Burlington,
ON, Canada). The somatostatin (Barbar) antibody, puriﬁed
by aﬃnity chromatography, was a gift from Dr. P. Brazeau,
Universit´ ed eM o n t r ´ eal, Montreal, Canada. The goat poly-
clonal anti-CCK-1 receptor antibody (7509) was raised
against the rat internal peptide (KFDASQKKSAKEKR) and
thegoatpolyclonalanti-CCK-2receptorantibody(6767)was
raised against the human internal peptides CCK-2 (FDGDS-
DSDSQSRVRNQ). These two antibodies and corresponding
p e p t i d e sw e r eg i f t sf r o mD r .J .V o s k u i l( E v e r e s tB i o t e c h ,
Oxfordshire, UK).
Cell Culture. The rat RIN-14B cell line is a secondary
clone derived from the RIN-m rat islet cell line; these cells
synthesize and secrete somatostatin [8]. Routinely, the cells
were grown on Petri dishes in RPMI 1640 (for RIN-14B) and
DMEM (for COS cells) media containing 25mM glucose,
10% fetal bovine serum (FBS), penicillin (100UmL−1),
streptomycin (100μgmL −1), 2mM L-glutamine, 10mM
HEPES, 1mM sodium pyruvate, and 1.5gL−1 sodium
bicarbonate. Cells were kept in culture at 37◦Ci na5 %C O 2
humidiﬁed atmosphere. The culture media were changed
every other day; they were passed weekly by trypsin (0.25%)-
EDTA (2.2mM) detachment and subcultured every week at
ar a t i oo f1:7 .
Growth Assay. Cells were plated in 60 mm diameter Petri
dishes at a density of 0.2 × 106 mL−1 (4mL/dish). The
next day, cells were transferred to RPMI 1640-0.5% heat
inactivated FBS and adapted overnight to grow in this
medium before addition of peptides, antiserum, and CCK-
receptor antagonist. The medium was changed daily and
cells were supplemented also daily with Cae (10−10 M), PG
(10−5 M), and SS-14 (10−9 M) alone or in combination with
L-364,718 (10−7 M) or Barbar (0.25μgmL −1). Cell growth
was measured after 1, 2, 3, 4, and 5 days with a cell counter
(Coulter counter).
SDS-PAGE and Western Blot. The membranes of the RIN-
14BandCOScellswerepreparedasdescribedin[12].Brieﬂy,
cells were resuspended in a homogenization buﬀer (10mM
HEPES, pH 7.5, 250mM sucrose, 1mM EGTA, 1mM EDTA,
0,5mM PMSF, 20μM leupeptin, 1μM aprotinin, and 2μM
pepstatin), homogenized using a Potter homogenizer and
sonicated for 10 seconds (40% power). The membranes were
then collected by centrifugation at 30000g for 30 minutes at
4◦C using a Beckman TLS-55 rotor (Palo Alto, Calif, USA)
and resuspended at 17mgmL−1 in the homogenization
buﬀer. Proteins were determined with the BCA assay of
Pierce using bovine serum albumin as standard.
Membrane proteins (100μg) were separated by elec-
trophoresis on a 10% SDS-polyacrylamide gel according to
[13] and transferred to nitrocellulose membranes (Sigma-
Aldrich). The membranes were blocked for 2 hours with
NAP-blocker (G Biosciences, St-Louis, Mo, USA) in TBST
(1 : 2v/v) and incubated overnight at 4◦C in NAP-
blocker: TBST (1 : 2v/v) with either the anti-CCK-1R 7509
(0.1μgmL −1) or the anti-CCK-2R 6767 (0.1μgmL −1) anti-
bodies. The blots were then washed in TBST and incubated
for 1 hour at RT◦ in NAP-blocker: TBST (1 : 2v/v) with
horseradish peroxidase-conjugated antigoat (1 : 10000).
Blots were washed with TBST and proteins were detected
by chemiluminescence using ECL immunodetection system
(AmershamBiosciences,Baied’Urf´ e,QC).Speciﬁcityofeach
CCK receptor antibody was established by preincubation of
e a c ha n t i b o d yf o r2h o u r sa tR T ◦ with its speciﬁc peptide
antigen:1μgmL −1 of7509and0.1μgmL −1 of6767peptides.
Statistical Analysis. Results were analyzed by the Student’s t-
test for comparison of independent samples with a probabil-
ity value of <.05 which is considered signiﬁcant.
3. Results
3.1. Presence of the CCK Receptor Subtypes on the RIN-
14B Cells. To establish the presence of both CCK receptor
subtypes on the RIN-14B cells, we used speciﬁc antibodies
raised against both receptors. With the speciﬁc CCK-1
receptor antibody (7509), we can see that the RIN-14B
cells express the CCK-1 receptor as a 75kDa protein. This
recognition by the antibody is speciﬁc because the band
totally disappeared with preincubation of the antibody with
the peptide used to develop this antibody (see Figure 1(a)).
Similarly, these cells also express the CCK-2 receptor, also
as a 75kDa protein identiﬁed with the antibody 6767;
speciﬁcityof thereceptor-antibody binding wasalsorevealed
with preincubation of the antibody with the peptide with
disappearance of the band (see Figure 1(b)).
To further strengthen the speciﬁcity of both CCK-1 and
CCK-2 receptor antibodies, we established the absence of
these two CCK receptors in COS cells known to be free of
these two receptors [14]. As shown in Figures 1(a) and 1(b),
both antibodies 7509 (anti-CCK-1) and 6767 (anti-CCK-2)
did not recognize the 75kDa band observed in the RIN-
14B cells. This observation further supports the speciﬁcity
of the two CCK receptor antibodies we used in this study to
demonstrate their presence in the RIN cells.
3.2. Eﬀect of Caerulein on RIN-14B Cell Growth. To deter-
mine if the CCK-1 analog caerulein can aﬀect the growth of
the RIN-14B cells, growth assays were performed. As shown
in Figure 2, caerulein, used at a concentration which totally
occupies the high aﬃnity CCK-1 receptors and causing
maximal amylase release from rat dispersed pancreatic aciniInternational Journal of Endocrinology 3
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Figure 1: Speciﬁcity of the CCK-1 and CCK-2 receptor antibodies established by Western blotting. Membrane from the RIN-14B and COS cells
(100μg) were used for Western blotting analysis with antibodies 7509 (0.1μgmL −1) and 6767 (0.1μgmL −1). Speciﬁcity was established by
preincubation of each primary antibody for 2 hours at RT with each receptor-speciﬁc peptide antigen (1μgmL −1 of 7509 and 0.1μgmL −1
of 6767 peptides). C: blue Coomassie gel coloration.
[15], caused signiﬁcant reductions in RIN-14B cell growth
from day 3 to day 5 of culture. The percentage of growth
inhibition at day 5 reached 12%. The observation that this
inhibition by caerulein was totally reversed by the speciﬁc
CCK-1receptorantagonistL-364718indicatesthattheCCK-
1 receptors are involved in this process of growth inhibition.
To eliminate the possibility that somatostatin released in
response to caerulein [11] could be responsible for growth
inhibition by the CCK analog, cells were also incubated with
an SS antibody along with caerulein; in no time did we
observe a diﬀerence between growth in the caerulein group
alone and caerulein plus the SS antibody (data not shown).
As shown in Figure 4, the SS antibody prevented growth
inhibition by SS alone.
3.3. Eﬀect of Pentagastrin on RIN-14B Cell Growth. To estab-
lish if the CCK-2 agonist pentagastrin could aﬀect growth
of these RIN-14B cells, growth assays were also performed.
The results indicate that contrary to what was observed
with occupation of the CCK-1 receptors, occupation of the
CCK-2 receptors by 10μM pentagastrin, a gastrin analog,
had no eﬀect on RIN-14B cell growth over the 5-day
period examined (see Figure 3). This strongly indicates that
occupation of the CCK-2 receptors did not alter the growth
of the RIN-14B cells.
3.4. Eﬀect of Somatostatin on RIN-14B Cell Growth. To verify
if somatostatin could have an inhibitory eﬀect on growth
of the cells responsible for its synthesis, the RIN-14B cells
were incubated for up to ﬁve days in the presence of
1nM somatostatin-14. As shown in Figure 4, somatostatin
signiﬁcantly reduced growth of the RIN-14B cells by 11.3%
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Figure 2: Growth control of the RIN-14B cells by the CCK-1 receptor
agonist caerulein (Cae) and the receptor’s speciﬁc antagonist, L-
364718. Cells were grown for up to 120 hours in the presence
of 0.1nM caerulein ± 0.1μM L-364718. Medium and drugs were
changed daily and cells were counted daily for up to 5 days. In
this experiment, results represent data collected from two separate
experiments with four wells per group; overall they represent 8
diﬀerent wells in each group. ∗Signiﬁcantly diﬀerent than control
at P<. 05.
after 5 days of culture; this inhibitory eﬀect was already
signiﬁcant after 2 days of culture. Addition of a somatostatin
antibody to the culture medium to neutralize endogenous
SS released by the cells had no eﬀect on their growth;
however its addition to exogenous somatostatin reversed its
growth inhibition. These results indicate that endogenous4 International Journal of Endocrinology
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Figure 3: Growth control of the RIN-14B cells by the CCK-2 receptor
agonist pentagastrin (PG). Cells were grown for up to 120 hours in
t h ep r e s e n c eo f1 0μM PG. Medium and PG were changed daily and
cells were counted daily for up to 5 days. Results are the means ± SE
of 5 wells per point in each group.
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Figure 4: Growth control of the RIN-14B cells by somatostatin and a
speciﬁc somatostatin antibody. Cells were grown for up to 120 hours
in the presence of 1nM somatostatin (SS) ± 0.25μgmL −1 of SS
antibody (Ab anti-SS) or Ab anti-SS alone. Medium and drugs were
changed daily and cells were counted daily for up to 5 days. Results
arethemeans ±SEof5wellsperpointineachgroup. ∗Signiﬁcantly
diﬀerent than control at P<. 05.
somatostatin released from these cells did not reach the
concentration needed to inhibit their growth but when
appliedattheneededconcentration,exogenoussomatostatin
can inhibit their growth.
4. Discussion
This study reports for the ﬁrst time that (1) the SS-secreting
RIN-14BcellsexpressthetwoknownandcharacterizedCCK
receptor subtypes; (2) occupation of the CCK-1 receptor
subtype leads to inhibition of these cells’ growth, while
occupation of the CCK-2 receptor subtype fails to stimulate
or inhibit such growth; (3) somatostatin can also inhibit
growthoftheseRIN-14Bcellsprobablythroughanautocrine
mechanism.
In contrast to substances which can control somatostatin
secretion, nothing is currently known about those responsi-
ble for delta cells’ growth. The observation that the RIN-14B
cells express the two CCK receptor subtypes is not unique
to these cells. Indeed, expression of both receptor subtypes
has been documented in normal rat pancreatic acini with a
predominance of the CCK-1 subtype over that of the CCK-
2[ 16] .T h e s et w or e c e p t o r sw e r ea l s or e p o r t e di nn o r m a l
human and rat islets but on diﬀerent cell types, the CCK-1
receptors on alpha and beta cells and the CCK-2 receptors
on the delta cells using two diﬀerent antibodies [17].
Studies performed in rats demonstrated that in pancreatic
malignancies, the CCK-1 receptor is overexpressed while
the CCK-2 receptor is newly expressed [18]. In human
pancreatic tumors however, the distribution of the two CCK
receptor subtypes is still controversial. Indeed, by using the
PCR technique, one study reported the presence of the
C C K - 2r e c e p t o r si na l ls a m p l e so fn o r m a lp a n c r e a sa n d
pancreatic adenocarcinoma; the CCK-1 receptor expression
could not be detected in normal pancreatic samples but
it appeared in all samples of pancreatic adenocarcinomas
[19]. By receptor autoradiography, the CCK-2 receptor was
found occasionally in pancreatic tumors while the CCK-
1 receptor was mostly expressed in these tumors [20].
These data emphasize that the expression of these two
CCK receptor subtypes in many cancer cell types may
be an important indicator of the inﬂuence of CCK and
gastrin of local or systemic origin on the growth of these
cancers.
Indeed, in Elas CCK-2 receptor transgenic mice, the
growth rate of their pancreas was increased by 40% after
birth between 40 and 110 days of age; this expression
had a key role in the development of pre- and neoplastic
lesions in their pancreas [21] .W h i l ee v e r y o n ea g r e e st h a t
occupation of the CCK-1 receptors in the pancreas of
rats [22] and other rodents led to growth of the organ,
its presence and stimulation in MiaPaCa-2 and Panc-
1 cells led to growth inhibitory responses [23]. Occu-
pation of the CCK-2 receptor also resulted in surpris-
ing opposite eﬀects when transfected in CHO and Swiss
3T3 cells. It inhibited proliferation and DNA synthesis in
the CHO-CCK-2 cells while stimulation occurred in the
Swiss 3T3-CCK-2 cells; these opposite eﬀects on growth
happened while CCK-8 stimulated the same common
second messenger pathways [24]. Growth inhibition was
also observed with occupation of the transfected CCK-2
receptors in the human pancreatic MiaPaca-2 and Panc-
1 cells [23]. Interestingly, coexpression of gastrin and
C C K - 2r e c e p t o r sw e r eo b s e r v e di n5 / 5a n d7 / 8h u m a n
gastric and colorectal cell lines and these cells maintain
an autocrine growth pathway [25]; the RIN-14B cells also
express gastrin although in small quantities (data not
shown).
When comparing all the above results with those
obtained with the RIN-14B cells, it seems that growth
inhibition observed in response to caerulein in this study
renders these RIN cells comparable to the transfected CCK-1International Journal of Endocrinology 5
MiaPaca-2 and Panc-1 cells [23]. Endogenous CCK also
resultedingrowthinhibitionofhumancholangiocarcinoma;
however, no speciﬁc antagonists of either CCK receptor
subtypes were used to conﬁrm which CCK receptor was
involved [26]. This study points out that CCK can inhibit
growth not only in cells transfected with both CCK receptor
subtypes. Moreover, the inhibition observed in these RIN
cells really resulted from occupation of the CCK-1 receptors
because it has been reversed by L-364718, a speciﬁc CCK-1
receptor antagonist.
Somatostatin can inhibit endogenous SS secretion from
the delta cells through an auto-feedback mechanism [27].
Although we have not investigated which somatostatin
receptors are present on the RIN-14B cells, it has been
reported that about 70% of the rat pancreatic delta cells
express the SS receptor subtypes 1–4 [28].
Since it is accepted that the antiproliferative eﬀect
of somatostatin results from its action via the endocrine
pathway, evidence also exists that somatostatin can also
act via an autocrine/paracrine pathway which has been
recently described in PC-3 and LNCaP cells, two human
prostate adenocarcinoma cell lines [29]. We do not believe
that growth of these RIN-14B cells is autoregulated by
somatostatin they release into the medium. This conclusion
is based on the following observations: (a) these cells grew in
a 0.5% inactivated FBS medium when they release into the
medium approximately 200pgmL−1 of somatostatin per 4
hours [11], and (b) they also grew at their control rates even
in the presence of 0.25μgmL −1 of a speciﬁc somatostatin
antibody; an autocrine regulated pathway would have shown
these cells grow at a rate above the controls in the presence
of the antibody. This was previously observed in vivo when
the trophic eﬀect of caerulein on the rat pancreas was
signiﬁcantly enhanced by a simultaneous administration
of a somatostatin antiserum, the same used in this study
[30].
Although endogenous somatostatin released by the RIN
cells does not seem suﬃcient to sustain growth inhibition,
these cells are however sensitive to somatostatin as they
exhibited growth inhibition in its presence at a higher
concentration. The magnitude of inhibition is comparable
to what was previously described in AR4-2J cells where
at 10nM, the hormone caused a 25% growth inhibi-
tion over a 96-hour period [31]. This inhibitory eﬀect
of somatostatin on the RIN cells proliferation is speciﬁc
since prevented by the presence of the somatostatin anti-
body.
In conclusion, our data indicate for the ﬁrst time that the
somatostatin RIN-14B cells possess the two CCK receptor
subtypes, and that their proliferation can be negatively
aﬀected by occupation of the CCK-1 receptor subtype and
exogenous somatostatin.
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